Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
RARE filed a patent for "compositions and methods for treating conditions associated with bsep deficiency" on Wed, July 26, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
